Manufacturing Split Genentech / Roche & Novartis
| Avastin Sales |
2010 Q2 |
2010 Q3 |
2010 Q4 |
2011 Q1 |
2011 Q2 |
2011 Q3 |
|---|---|---|---|---|---|---|
| US Made & Sold |
814,872 | 820,453 | 800,139 | 708,539 | 719,967 | 688,966 |
| US Made & ex-US Sold |
355,742 | 338,929 | 415,576 | 580,981 | 548,710 | 587,975 |
| ex-US Made & Sold |
426,277 | 435,325 | 430,503 | 307,941 | 314,028 | 304,155 |
| Total | 1,596,892 | 1,594,707 | 1,646,218 | 1,597,461 | 1,582,705 | 1,581,095 |
| US Made & Sold |
51% | 51% | 49% | 44% | 45% | 44% |
| US Made & ex-US Sold |
22% | 21% | 25% | 36% | 35% | 37% |
| ex-US Made & Sold |
27% | 27% | 26% | 19% | 20% | 19% |
| Herceptin Sales |
2010 Q2 |
2010 Q3 |
2010 Q4 |
2011 Q1 |
2011 Q2 |
2011 Q3 |
|---|---|---|---|---|---|---|
| US Made & Sold |
406,222 | 410,563 | 416,611 | 409,854 | 442,903 | 445,395 |
| US Made & ex-US Sold |
312,792 | 306,085 | 425,303 | 423,053 | 642,670 | 495,086 |
| ex-US Made & Sold |
630,498 | 584,286 | 567,396 | 558,661 | 474,402 | 702,416 |
| Total | 1,349,512 | 1,300,934 | 1,409,310 | 1,391,568 | 1,559,975 | 1,642,898 |
| US Made & Sold |
30% | 32% | 30% | 29% | 28% | 27% |
| US Made & ex-US Sold |
23% | 24% | 30% | 30% | 41% | 30% |
| ex-US Made & Sold |
47% | 45% | 40% | 40% | 30% | 43% |
| Lucentis Sales |
2010 Q2 |
2010 Q3 |
2010 Q4 |
2011 Q1 |
2011 Q2 |
2011 Q3 |
|---|---|---|---|---|---|---|
| US Made & Sold |
300,501 | 326,840 | 360,911 | 378,451 | 409,674 | 422,335 |
| US Made & ex-US Sold |
398,389 | 418,536 | 443,773 | 509,307 | 533,745 | 630,474 |
| ex-US Made & Sold |
- | - | - | - | - | - |
| Total | 698,890 | 745,376 | 804,684 | 887,757 | 943,418 | 1,052,809 |
| US Made & Sold |
43% | 44% | 45% | 43% | 43% | 40% |
| US Made & ex-US Sold |
57% | 56% | 55% | 57% | 57% | 60% |
| ex-US Made & Sold |
0% | 0% | 0% | 0% | 0% | 0% |
| Xolair Sales |
2010 Q2 |
2010 Q3 |
2010 Q4 |
2011 Q1 |
2011 Q2 |
2011 Q3 |
|---|---|---|---|---|---|---|
| US Made & Sold |
145,245 | 165,109 | 170,001 | 164,621 | 167,608 | 184,837 |
| US Made & ex-US Sold |
- | - | - | - | - | - |
| ex-US Made & Sold |
80,632 | 85,945 | 93,388 | 103,133 | 110,034 | 126,037 |
| Total | 225,878 | 251,055 | 263,389 | 267,754 | 277,642 | 310,874 |
| US Made & Sold |
64% | 66% | 65% | 61% | 60% | 59% |
| US Made & ex-US Sold |
0% | 0% | 0% | 0% | 0% | 0% |
| ex-US Made & Sold |
36% | 34% | 35% | 39% | 40% | 41% |
| Total Sales |
2010 Q2 |
2010 Q3 |
2010 Q4 |
2011 Q1 |
2011 Q2 |
2011 Q3 |
|---|---|---|---|---|---|---|
| US Made & Sold |
1,666,840 | 1,722,965 | 1,747,662 | 1,661,465 | 1,740,152 | 1,741,534 |
| US Made & ex-US Sold |
1,081,147 | 1,063,551 | 1,284,652 | 1,513,340 | 1,725,125 | 1,713,535 |
| ex-US Made & Sold |
1,137,407 | 1,105,556 | 1,091,287 | 969,735 | 898,464 | 1,132,608 |
| Total | 3,885,394 | 3,892,072 | 4,123,601 | 4,144,540 | 4,363,741 | 4,587,677 |
| US Made & Sold |
43% | 44% | 42% | 40% | 40% | 38% |
| US Made & ex-US Sold |
28% | 27% | 31% | 37% | 40% | 37% |
| ex-US Made & Sold |
29% | 28% | 26% | 23% | 21% | 25% |

